key: cord-0973785-m18ttqcw
authors: Mungmunpuntipantip, Rujittika; Wiwanitkit, Viroj
title: Guillain-Barre syndrome, Facial Diplegia and Pfizer COVID-19 vaccine
date: 2021-10-29
journal: J Emerg Med
DOI: 10.1016/j.jemermed.2021.10.038
sha: b52a544b68397e862937f4a673edf2f40b37aa94
doc_id: 973785
cord_uid: m18ttqcw

nan

." GS following vaccination is a possible COVID-19 vaccine adverse event. It is necessary to exclude other possible causes by serological examination for other infections.

Indeed, another possible cause of the problem is hyperviscosity following vaccination. After COVID-19 vaccination, hyperviscosity might be induced [2] and the hyperviscosity is a possible cause of a temporary manifestation as GBS [3] and diplegia [4] .

Guillain-Barre Syndrome Presenting as Facial Diplegia after COVID-19 Vaccination: A Case Report

Expected Viscosity After COVID-19 Vaccination, Hyperviscosity and Previous COVID-19

Safety of Therapeutic Plasma Exchange for the Treatment of Guillain-Barre Syndrome in Polycythemia Vera

Neonatal hyperviscosity. II. Effect of partial plasma exchange transfusion

None